

CAPRICOR THERAPEUTICS, INC.  
 Form 3  
 December 02, 2013

**FORM 3** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

<p>1. Name and Address of Reporting Person *</p> <p>Â Smith Rachel</p> <p>(Last) (First) (Middle)</p> <p>C/O CAPRICOR THERAPEUTICS, INC.,Â 8840 WILSHIRE BLVD., 2ND FLOOR</p> <p>(Street)</p> <p>BEVERLY HILLS,Â CAÂ 90211</p> <p>(City) (State) (Zip)</p>	<p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>11/20/2013</p>	<p>3. Issuer Name and Ticker or Trading Symbol</p> <p>CAPRICOR THERAPEUTICS, INC. [NLTXD]</p>	<p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p><input type="checkbox"/> Director <input type="checkbox"/> 10% Owner</p> <p><input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other</p> <p>(give title below) (specify below)</p> <p>VP of Research and Development</p>	<p>5. If Amendment, Date Original Filed(Month/Day/Year)</p>	<p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p><input checked="" type="checkbox"/> Form filed by One Reporting Person</p> <p><input type="checkbox"/> Form filed by More than One Reporting Person</p>
--	---	---	---	---	--

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	--	---	---	--

Edgar Filing: CAPRICOR THERAPEUTICS, INC. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (right to buy)	01/01/2008 <sup>(1)</sup>	01/01/2018	COMMON STOCK	20,748	\$ 0.16	D	Â
Stock Option (right to buy)	01/01/2010 <sup>(2)</sup>	01/01/2020	COMMON STOCK	16,598	\$ 0.19	D	Â
Stock Option (right to buy)	07/27/2012 <sup>(3)</sup>	07/27/2022	COMMON STOCK	38,384	\$ 0.37	D	Â
Stock Option (right to buy)	11/13/2012 <sup>(4)</sup>	11/13/2022	COMMON STOCK	75,732	\$ 0.37	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships				Other
	Director	10% Owner	Officer		
Smith Rachel C/O CAPRICOR THERAPEUTICS, INC. 8840 WILSHIRE BLVD., 2ND FLOOR BEVERLY HILLS, CA 90211	Â	Â	Â	VP of Research and Development	Â

## Signatures

/s/ Linda Marban, as  
Attorney-in-Fact

11/30/2013

Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Vesting schedule is as follows: This option is deemed fully vested.
- (2) Vesting schedule is as follows: The shares of common stock subject to this option vest 25% per year over 4 years commencing January 1, 2011.
- (3) Vesting schedule is as follows: The shares of common stock subject to this option vest 25% per year over 4 years commencing July 27, 2013.
- (4) Vesting schedule is as follows: The shares of common stock subject to this option vest 25% per year over 4 years commencing November 13, 2013.

Â

### Remarks:

Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.